Theme: Encompassing the Possibilities and Novel Targets in Prostate Cancer Research

Prostate Cancer 2016

Prostate Cancer 2016

Conference Series LLC invites all the participants from all over the world to attend ‘2nd International Conference on Prostate Cancer and Therapeutics’ to be held during August 22-23, 2016 at Philadelphia, USA which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions. 

Prostate Cancer 2016 is a global platform to discuss and learn about Prostate Cancer: Current Topics and Future Perspectives, Prostate Cancer and Its Complications, Prostate Cancer Treatment, Living and Managing Prostate Cancer, Prostate Cancer in Market, Clinical Case Study, Prostate Cancer and Alternative Medicine, Latest Research on Prostate Cancer, Technological Tools in Prostate Cancer and Emerging focus in Prostate Cancer Research.The Prostate Cancer World Congress 2016 is the world’s largest multidisciplinary prostate cancer meeting. Prostate cancer conferences include scientific keynote lectures, symposia, workshops, exhibitions with the support from Oncology Society and American Oncology Society. Cancer conferences include European oncology conferencessurgical oncology global cancer conference and cancer conferences

Conference Series LLC, the host of this conference is comprised of 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+Workshops on diverse Medical, Pharmaceutical, Clinical, Engineering, Science, Technology, Business and Management field is organizing conferences all over the globe

Track 1 - Prostate cancer

Prostate cancer is an abnormal and uncontrolled growth of cells found in your prostate gland. Causes of prostate cancer include age, genetics, diet, medication, obesity and sexually transmitted diseases. Almost all prostate cancers are adenocarcinomas. Interventional oncology procedures provide minimally invasive, targeted treatment of prostate cancer. Prostate cancer often has no early symptoms. Advanced prostate cancer can cause men to urinate more often or have a weaker flow of urine, but these symptoms can also be caused by benign prostate conditions. Molecular Oncology of Prostate Cancer emphasizes the genes, proteins and biologic pathways that are being evaluated today and will be tested in the future to derive the molecular signature of each newly diagnosed prostate cancer. Cellular Oncology involves in basic and translational cancer research on the cell and tissue engineering of prostate. Prostate cancer usually grows very slowly. Most men with prostate cancer are older than 65 years and do not die from the disease. Finding and treating prostate cancer before symptoms occur may not improve health or help you live longer. 

Related Oncology Conferences | Cancer Conferences | Oncology Meetings

Oral Cancer Conference, August 18-20 2016, Portland, USA; Surgical Oncology Conference, August 29-31 2016, Sao Paulo, Brazil; Cancer Diagnostics Conference, May 8-10, 2017 Dubai, UAE; 3rd Prostate Cancer Conference, June 26-28, 2017 Baltimore, USA; Lymphoma Conference, July 24-26, 2017 Rome, Italy; 14th Urological Association of Asia Congress, July 20-24, 2016 Suntec, Singapore; 17th Asia-Pacific Prostate Cancer Conference, August 31- September 3, 2016 Melbourne, Australia; ASCO Genitourinary Cancers Symposium, February, 16-18, 2017 Orlando, USA; 2nd International Prostate Cancer Symposium, August 6 -7, 2016 Moscow, Russia, 13th Meeting of the EAU Robotic Urology Section, September 14-16, 2016 Milan – Italy; 11th Annual Congress of Russian Association of Oncological Urology, 05-07, 2016 Moscow, Russia; 36th International Urology Congress, October 20-23, 2016 Argentina, South America, 27th International Prostate Cancer Update, January 24-27, 2017 Colorado, USA.

Track 2 - Prostate Cancer and Its Complications

Prostate cancer can cause a number of complications from local and distant spread which include blockage of the bladder by urethral obstruction, bleeding in the urine, blockage of the tubes draining the kidneys into the bladder (ureters), pelvic pain, bony pain, tiredness and death. Prostate cancer most commonly spreads to lymph node which is known as Lymph node cancer. Long-term complications which can arise following surgery include Impotence, Incontinence, Obstruction and disease recurrence. Cancers of the prostate can spread to esophagus which is known as Esophageal cancer. However, the lack of testosterone can lead to a number of side effects which include Osteoporosis, Diabetes, Cardiovascular disease and Weight gain. A recent large study showed an increased risk of pancreas cancer in people with a father, brother or son diagnosed with prostate cancer.

Related Oncology Conferences | Cancer Conferences | Oncology Meetings

12th World Cancer Conference, September 26-28, 2016 London, UK; 13th Global Oncologists Summit, October 17-19 2016, Dubai, UAE; Global Summit on Melanoma, September 25-26, 2017 Rome, Italy; Multiple Myeloma Conference, October 15-17, 2017 Milan, Italy; Radiology Conference, October 23-25, 2017 Chicago, USA; 6th Annual Asia-Pacific Prostate Society Conference, September 9 -10 Seoul, Korea; 68th Annual German Society of Urology Congress, September 28-October 1, 2016 Leipzig, Germany; 72nd Annual Canadian Urological Association Meeting, June 25-27, 2017 Toronto, Canada; 4th Annual Immuno-Oncology Summit, August 29-September 2, 2016 Boston, USA; 2nd Biomarkers, Diagnostics & Clinical Research Conference, September 19-20 Boston, USA; Biomarkers and Targeted Therapeutics in Sjögren’s (BATTS) Conference, September 19-22, 2016 Oklahoma, USA; NCRI Cancer Conference, November 6-9, 2016 Liverpool, UK; 6th Munich Biomarker Conference, November 29-30, 2016 Munchen, Germany; Annual Meeting of American Association of Genitourinary Surgeons, April 27-30, 2017 Florida, USA.

Track 3 - Prostatitis

Prostatitis is a frequently painful condition that involves inflammation of the prostate and sometimes the areas around the prostate. Types of Prostatitis include acute bacterial prostatitis (ABP), chronic bacterial prostatitis (CBP), nonbacterial prostatitis and prostatodynia and may cause infectious diseases. Causes and Symptoms of Prostatitis include: urinary tract infection, recent bladder infection, enlarged prostate and symptoms-frequent urge to urinate, difficulty urinating, pain or burning during urination, chills and fever. The treatment for prostatitis depends on the underlying cause and type of prostatitis. Treatment modalities may include the following: Antibiotics, Anti-inflammatory medications, Alpha-blockers, Lifestyle changes and Acupuncture. Prevention of prostatitis includes practice good hygiene and keeps your penis clean, drink enough fluids to cause regular urination and early treatment of a possible urinary tract infection.

Related Oncology Conferences | Cancer Conferences | Oncology Meetings

Molecular Biomarkers Conference, September 15-17 2016 Berlin, Germany; Cervical Cancer Conference, September 22-23 2016, Vienna, Austria; Surgical Oncology Conference, October 23-25, 2017 Chicago, USA; 2nd Cervical Cancer Conference, October 29 -31, 2017 Brussels, Belgium; Cancer World Conventaion, November 26-28, 2017 Frankfurt, Germany; 89th Annual Italian Society of Urology Congress, October 15-18, 2016 Venezia Italy; 62nd Annual Meeting of Czech Urological Society, October 19-21, 2016 Czech Budejovice, Czech Republic; ESMO 2017 Congress, September 08-12, 2017 Madrid, Spain; International Cancer Education Conference, September 14-16, 2016 Bethesda, USA; 16th Biennial Meeting of the International Gynecologic Cancer Society, October 29-31​ Lisbon, Portugal; World Cancer Congress , October 31 - November 3 Paris, France, Malaysia Urology Conference, November 24-28,2016 Kuala Lumpur, Malaysia; Annual AUA Meeting, May 12-16, 2017 Boston, USA.

Track-4 Prostatic Calcification

Prostatic calcification is a common finding, especially after the age of 50. They may be solitary but usually occur in clusters. Interventional oncology procedures provide minimally invasive, targeted treatment of prostate cancer and can also be treated by using cancer therapy. Variable appearance from fine granules to irregular lumps and can range in size from 1 to 40mm. If there is significant prostatic hypertrophy the calcifications can project well above the pubic symphysis. Prostatic calcification is most often an incidental; asymptomatic finding but it can cause symptoms such as dysuria, infection, haemautira, obstruction or Chronic Pelvic Pain and can be detected by using cancer biomarkers.

Related Oncology Conferences | Cancer Conferences | Oncology Meetings

Oral Cancer Conference, August 18-20 2016, Portland, USA; Surgical Oncology Conference, August 29-31 2016, Sao Paulo, Brazil; Cancer Diagnostics Conference, May 8-10, 2017 Dubai, UAE; 3rd Prostate Cancer Conference, June 26-28, 2017 Baltimore, USA; Lymphoma Conference, July 24-26, 2017 Rome, Italy; 14th Urological Association of Asia Congress, July 20-24, 2016 Suntec, Singapore; 17th Asia-Pacific Prostate Cancer Conference, August 31- September 3, 2016 Melbourne, Australia; ASCO Genitourinary Cancers Symposium, February, 16-18, 2017 Orlando, USA; 2nd International Prostate Cancer Symposium, August 6 -7, 2016 Moscow, Russia, 13th Meeting of the EAU Robotic Urology Section, September 14-16, 2016 Milan – Italy; 11th Annual Congress of Russian Association of Oncological Urology, 05-07, 2016 Moscow, Russia; 36th International Urology Congress, October 20-23, 2016 Argentina, South America, 27th International Prostate Cancer Update, January 24-27, 2017 Colorado, USA.

Track-5 Prostate Staging

Prostate Staging is a way of describing where the cancer is located, if or where it has spread, and whether it is affecting other parts of the body. Doctors use cancer diagnostic methods to find out the cancer's stage, so staging may not be complete until all of the tests are finished. Staging for prostate cancer also involves looking at test results to find out if the cancer has spread from the prostate to other parts of the body. Knowing the stage helps the doctor to decide what kind of treatment is best and can help predict a patient's prognosis, which is the chance of recovery. There are different stage descriptions for different types of cancer. The Prostate Cancer World Congress 2016 is the world’s largest multidisciplinary prostate cancer meeting.

Related Oncology Conferences | Cancer Conferences | Oncology Meetings

12th World Cancer Conference, September 26-28, 2016 London, UK; 13th Global Oncologists Summit, October 17-19 2016, Dubai, UAE; Global Summit on Melanoma, September 25-26, 2017 Rome, Italy; Multiple Myeloma Conference, October 15-17, 2017 Milan, Italy; Radiology Conference, October 23-25, 2017 Chicago, USA; 6th Annual Asia-Pacific Prostate Society Conference, September 9 -10 Seoul, Korea; 68th Annual German Society of Urology Congress, September 28-October 1, 2016 Leipzig, Germany; 72nd Annual Canadian Urological Association Meeting, June 25-27, 2017 Toronto, Canada; 4th Annual Immuno-Oncology Summit, August 29-September 2, 2016 Boston, USA; 2nd Biomarkers, Diagnostics & Clinical Research Conference, September 19-20 Boston, USA; Biomarkers and Targeted Therapeutics in Sjögren’s (BATTS) Conference, September 19-22, 2016 Oklahoma, USA; NCRI Cancer Conference, November 6-9, 2016 Liverpool, UK; 6th Munich Biomarker Conference, November 29-30, 2016 Munchen, Germany; Annual Meeting of American Association of Genitourinary Surgeons, April 27-30, 2017 Florida, USA.

Track-6 Screening for Prostate Cancer

Tests commonly used to screen for prostate cancer include PSA screening - Prostate specific antigen (PSA) test measures the level of PSA in the blood. PSA is a substance made by the prostate. The levels of PSA in the blood can be higher in men who have prostate cancer. The main type of surgery for prostate cancer is known as a radical prostatectomy. In this operation, the surgeon removes the entire prostate gland plus some of the tissue around it, including the seminal vesicles. The Prostascint scan was developed in order to help doctors detect the spread of prostate cancer to other parts of the body, particularly the lymph node cancer. Clinical case discussions on prostate cancer include Case Reports on Prostate Cancer, Case Study: Castrate-Resistant Prostate Cancer. Proton therapy for prostate cancer is a treatment option that involves using a focused ray of proton particles to destroy cancerous tissues. The cancer diagnosis and screening segment is expected to total $12.1 billion in 2012 and $17.4 billion in2017, a CAGR of 7.5%.

Related Oncology Conferences | Cancer Conferences | Oncology Meetings

Molecular Biomarkers Conference, September 15-17 2016 Berlin, Germany; Cervical Cancer Conference, September 22-23 2016, Vienna, Austria; Surgical Oncology Conference, October 23-25, 2017 Chicago, USA; 2nd Cervical Cancer Conference, October 29 -31, 2017 Brussels, Belgium; Cancer World Conventaion, November 26-28, 2017 Frankfurt, Germany; 89th Annual Italian Society of Urology Congress, October 15-18, 2016 Venezia Italy; 62nd Annual Meeting of Czech Urological Society, October 19-21, 2016 Czech Budejovice, Czech Republic; ESMO 2017 Congress, September 08-12, 2017 Madrid, Spain; International Cancer Education Conference, September 14-16, 2016 Bethesda, USA; 16th Biennial Meeting of the International Gynecologic Cancer Society, October 29-31​ Lisbon, Portugal; World Cancer Congress , October 31 - November 3 Paris, France, Malaysia Urology Conference, November 24-28,2016 Kuala Lumpur, Malaysia; Annual AUA Meeting, May 12-16, 2017 Boston, USA

Track-7 Prostate Surgery

Radical prostatectomy is an operation to remove the prostate gland and some of the tissue around it. It is done to remove prostate cancer. This operation may be done by open surgery or it may be done by laparoscopic surgery. In open surgery, the surgeon makes an incision to reach the prostate gland. Cancer Sciences is a study of cancer cells that causes tumor and technically the therapy is processed. Curative treatment options include Cancer therapies such as radical prostatectomy (RP), external beam radiotherapy and brachytherapy. Active surveillance is a strategy of close monitoring, typically using serum PSA, repeat prostate biopsies and/or MRI, keeping curative treatment in reserve for those with early evidence of disease progression. Anti-cancer drugs are also called anti-neoplastic agents or chemotherapeutic agents which are used to treat prostate cancer.

Related Oncology Conferences | Cancer Conferences | Oncology Meetings

Oral Cancer Conference, August 18-20 2016, Portland, USA; Surgical Oncology Conference, August 29-31 2016, Sao Paulo, Brazil; Cancer Diagnostics Conference, May 8-10, 2017 Dubai, UAE; 3rd Prostate Cancer Conference, June 26-28, 2017 Baltimore, USA; Lymphoma Conference, July 24-26, 2017 Rome, Italy; 14th Urological Association of Asia Congress, July 20-24, 2016 Suntec, Singapore; 17th Asia-Pacific Prostate Cancer Conference, August 31- September 3, 2016 Melbourne, Australia; ASCO Genitourinary Cancers Symposium, February, 16-18, 2017 Orlando, USA; 2nd International Prostate Cancer Symposium, August 6 -7, 2016 Moscow, Russia, 13th Meeting of the EAU Robotic Urology Section, September 14-16, 2016 Milan – Italy; 11th Annual Congress of Russian Association of Oncological Urology, 05-07, 2016 Moscow, Russia; 36th International Urology Congress, October 20-23, 2016 Argentina, South America, 27th International Prostate Cancer Update, January 24-27, 2017 Colorado, USA.

Track 8 - Radical Prostatectomy

For laparoscopic surgery, the surgeon makes several small incisions in the belly. Robotic-assisted laparoscopic radical prostatectomy is surgery done through small incisions in the belly with robotic arms that translate the surgeon's hand motions into finer and more precise action. Risks after surgery are Problems controlling bowel movements, Problems controlling urine, Erectile Dysfunction, Injury to the rectum, Urethral stricture. As a segment, surgical and radiation therapy should total $9 billion in 2012 and nearly $14.3 billion in 2017, a CAGR of 9.7%.A prosthesis is a device designed to replace a missing part of the body or to make a part of the body work better. Transurethral resection of the prostate (TURP) is a type of prostate surgery done to relieve moderate to severe urinary symptoms caused by an enlarged prostate.

Related Oncology Conferences | Cancer Conferences | Oncology Meetings

12th World Cancer Conference, September 26-28, 2016 London, UK; 13th Global Oncologists Summit, October 17-19 2016, Dubai, UAE; Global Summit on Melanoma, September 25-26, 2017 Rome, Italy; Multiple Myeloma Conference, October 15-17, 2017 Milan, Italy; Radiology Conference, October 23-25, 2017 Chicago, USA; 6th Annual Asia-Pacific Prostate Society Conference, September 9 -10 Seoul, Korea; 68th Annual German Society of Urology Congress, September 28-October 1, 2016 Leipzig, Germany; 72nd Annual Canadian Urological Association Meeting, June 25-27, 2017 Toronto, Canada; 4th Annual Immuno-Oncology Summit, August 29-September 2, 2016 Boston, USA; 2nd Biomarkers, Diagnostics & Clinical Research Conference, September 19-20 Boston, USA; Biomarkers and Targeted Therapeutics in Sjögren’s (BATTS) Conference, September 19-22, 2016 Oklahoma, USA; NCRI Cancer Conference, November 6-9, 2016 Liverpool, UK; 6th Munich Biomarker Conference, November 29-30, 2016 Munchen, Germany; Annual Meeting of American Association of Genitourinary Surgeons, April 27-30, 2017 Florida, USA.

Track 9 - Diagnosis of Prostate Cancer

Early prostate cancers usually don’t cause symptoms, but more advanced cancers are sometimes first found because of symptoms they cause. Whether cancer is suspected based on cancer diagnosis tests or symptoms, the actual diagnosis can only be made with a prostate biopsy. TRUS is often used to look at the prostate when a man has a high PSA level or has an abnormal DRE result. It is also used during a prostate biopsy to guide the needles into the right area of the prostate. Pathologists grade prostate cancers according to the Gleason system. This system assigns a Gleason grade, using numbers from 1 to 5 based on how many cells in the cancerous tissue look like normal prostate tissue and can be treated using radiation therapy.

Related Oncology Conferences | Cancer Conferences | Oncology Meetings

Molecular Biomarkers Conference, September 15-17 2016 Berlin, Germany; Cervical Cancer Conference, September 22-23 2016, Vienna, Austria; Surgical Oncology Conference, October 23-25, 2017 Chicago, USA; 2nd Cervical Cancer Conference, October 29 -31, 2017 Brussels, Belgium; Cancer World Conventaion, November 26-28, 2017 Frankfurt, Germany; 89th Annual Italian Society of Urology Congress, October 15-18, 2016 Venezia Italy; 62nd Annual Meeting of Czech Urological Society, October 19-21, 2016 Czech Budejovice, Czech Republic; ESMO 2017 Congress, September 08-12, 2017 Madrid, Spain; International Cancer Education Conference, September 14-16, 2016 Bethesda, USA; 16th Biennial Meeting of the International Gynecologic Cancer Society, October 29-31​ Lisbon, Portugal; World Cancer Congress , October 31 - November 3 Paris, France, Malaysia Urology Conference, November 24-28,2016 Kuala Lumpur, Malaysia; Annual AUA Meeting, May 12-16, 2017 Boston, USA.

Track 10 - Prostate Cancer Treatment

There are many treatment options for prostate cancer that is confined to the prostate gland. Historical standard options include Radical prostatectomy, External beam therapy and Active surveillance. Cancer that leads to bone metastasis and survival for bone cancers has improved in recent years by Bone marrow Cancer Survival. The newer options avoid or minimize some of the unpleasant side effects sometimes associated with the standard therapies. Bone cancer stages are important for the treatment of cancer. It can be treated using Bone Marrow Transplantation. These options include nerve-sparing radical prostatectomy, conformal external beam radiation therapy, image-guided radiation therapy, proton beam therapy and brachytherapy. Sarccoma cancer of prostate occurs in relatively younger men between the ages of 35 and 60.A digital rectal examination will be done to assess the prostate gland. A blood test will be performed to measure your PSA level and to assess your response to the blood cancer treatment. An elevated level of PSA can indicate the presence of prostate cancer.

Related Oncology Conferences | Cancer Conferences | Oncology Meetings

Oral Cancer Conference, August 18-20 2016, Portland, USA; Surgical Oncology Conference, August 29-31 2016, Sao Paulo, Brazil; Cancer Diagnostics Conference, May 8-10, 2017 Dubai, UAE; 3rd Prostate Cancer Conference, June 26-28, 2017 Baltimore, USA; Lymphoma Conference, July 24-26, 2017 Rome, Italy; 14th Urological Association of Asia Congress, July 20-24, 2016 Suntec, Singapore; 17th Asia-Pacific Prostate Cancer Conference, August 31- September 3, 2016 Melbourne, Australia; ASCO Genitourinary Cancers Symposium, February, 16-18, 2017 Orlando, USA; 2nd International Prostate Cancer Symposium, August 6 -7, 2016 Moscow, Russia, 13th Meeting of the EAU Robotic Urology Section, September 14-16, 2016 Milan – Italy; 11th Annual Congress of Russian Association of Oncological Urology, 05-07, 2016 Moscow, Russia; 36th International Urology Congress, October 20-23, 2016 Argentina, South America, 27th International Prostate Cancer Update, January 24-27, 2017 Colorado, USA.

Track 11 - Treating Advanced Prostate Cancer

Treatments that slow the spread of advanced prostate cancer and relieve symptoms often cause side effects. Some patients, often those who are older, decide that the risk of side effects outweighs the benefits of treatment. These patients may choose not to treat their advanced prostate cancerEndocrine therapy may reduce tumor size and levels of prostate specific antigen (PSA) in most men. Provenge is an immune therapy created by harvesting immune system or immune cells from a patient, genetically engineering them to fight prostate cancer, and then infusing them back into the patient.

Related Oncology Conferences | Cancer Conferences | Oncology Meetings

12th World Cancer Conference, September 26-28, 2016 London, UK; 13th Global Oncologists Summit, October 17-19 2016, Dubai, UAE; Global Summit on Melanoma, September 25-26, 2017 Rome, Italy; Multiple Myeloma Conference, October 15-17, 2017 Milan, Italy; Radiology Conference, October 23-25, 2017 Chicago, USA; 6th Annual Asia-Pacific Prostate Society Conference, September 9 -10 Seoul, Korea; 68th Annual German Society of Urology Congress, September 28-October 1, 2016 Leipzig, Germany; 72nd Annual Canadian Urological Association Meeting, June 25-27, 2017 Toronto, Canada; 4th Annual Immuno-Oncology Summit, August 29-September 2, 2016 Boston, USA; 2nd Biomarkers, Diagnostics & Clinical Research Conference, September 19-20 Boston, USA; Biomarkers and Targeted Therapeutics in Sjögren’s (BATTS) Conference, September 19-22, 2016 Oklahoma, USA; NCRI Cancer Conference, November 6-9, 2016 Liverpool, UK; 6th Munich Biomarker Conference, November 29-30, 2016 Munchen, Germany; Annual Meeting of American Association of Genitourinary Surgeons, April 27-30, 2017 Florida, USA.

Track 12 - Prostate Cancer and Alternative Medicine

Prostate cancer patients undergoing conventional therapies also can benefit from nutritional supplements and herbal support. Nutrition plays a very important role in cancer treatment. Prostate Oncology analytics provides evidence-based care, utilizes a counseling model within traditional preauthorization management for chemotherapeutic drugs, symptom-management drugs and supporting agents. Scientific evidence shows that nutrition and physical activity are the two most important modifiable risk factors to alter the course of cancer, prevent its occurrence, and stop its progression. Prostate oncologic emergency may be defined as any acute potentially morbid or life-threatening event directly or indirectly related to a patient's tumor or its treatment. Supplements are intended to provide nutritional support. Herbal medicines rarely have significant side effects when used appropriately and at suggested doses. Some types of cancers rarely spread to the brain, such as colon cancer or prostate cancer. Brain tumor treatment can be done by Radiation, Surgery and Chemotherapy which depends on the size and type of the tumor. Measures may be taken, starting 2 weeks before surgery, to prevent surgical complications, reduce pain and swelling, speed healing, support the immune system, and reduce or prevent the spread of cancer cells. Measures may be taken, continuing for 4 weeks after surgery, to prevent surgical complications, reduce pain and swelling, speed healing, support the immune system, and reduce or prevent the spread of cancer cells. 

Related Oncology Conferences | Cancer Conferences | Oncology Meetings

Molecular Biomarkers Conference, September 15-17 2016 Berlin, Germany; Cervical Cancer Conference, September 22-23 2016, Vienna, Austria; Surgical Oncology Conference, October 23-25, 2017 Chicago, USA; 2nd Cervical Cancer Conference, October 29 -31, 2017 Brussels, Belgium; Cancer World Conventaion, November 26-28, 2017 Frankfurt, Germany; 89th Annual Italian Society of Urology Congress, October 15-18, 2016 Venezia Italy; 62nd Annual Meeting of Czech Urological Society, October 19-21, 2016 Czech Budejovice, Czech Republic; ESMO 2017 Congress, September 08-12, 2017 Madrid, Spain; International Cancer Education Conference, September 14-16, 2016 Bethesda, USA; 16th Biennial Meeting of the International Gynecologic Cancer Society, October 29-31​ Lisbon, Portugal; World Cancer Congress , October 31 - November 3 Paris, France, Malaysia Urology Conference, November 24-28,2016 Kuala Lumpur, Malaysia; Annual AUA Meeting, May 12-16, 2017 Boston, USA.

Track 13 - Latest Research on Prostate Cancer

Scientists continue to look at new ways to prevent, treat, and diagnose prostate cancer. Although the specific underlying mechanisms of prostate carcinogenesis remain unknown, prostate cancer is thought to result from a combination of genetic and environmental factors altering key cellular processes. Research has already led to a number of advances in these areas. Some researchers think that diet may affect a man's chances of developing prostate cancer. Active mitochondrial mutagenesis in prostate cancer suggests a prominent role of increased cellular oxidative stress in neoplastic transformation and the increased susceptibility of neoplastic cells to oxidative damage. Some research suggests that high levels of testosterone may increase a man's risk of prostate cancer. As in the normal prostate, the initial stages of prostate cancer progression depend on androgens that increase proliferation and inhibit apoptosis. Researchers are studying changes in genes that may increase the risk for developing prostate cancer. Several studies have explored ways to prevent prostate cancer. Scientists are also looking at ways to stop prostate cancer from returning in men who have already been treated for the disease. Some researchers are working to develop new blood tests to detect the antibodies that the immune system produces to fight prostate cancer. 

Related Oncology Conferences | Cancer Conferences | Oncology Meetings

Oral Cancer Conference, August 18-20 2016, Portland, USA; Surgical Oncology Conference, August 29-31 2016, Sao Paulo, Brazil; Cancer Diagnostics Conference, May 8-10, 2017 Dubai, UAE; 3rd Prostate Cancer Conference, June 26-28, 2017 Baltimore, USA; Lymphoma Conference, July 24-26, 2017 Rome, Italy; 14th Urological Association of Asia Congress, July 20-24, 2016 Suntec, Singapore; 17th Asia-Pacific Prostate Cancer Conference, August 31- September 3, 2016 Melbourne, Australia; ASCO Genitourinary Cancers Symposium, February, 16-18, 2017 Orlando, USA; 2nd International Prostate Cancer Symposium, August 6 -7, 2016 Moscow, Russia, 13th Meeting of the EAU Robotic Urology Section, September 14-16, 2016 Milan – Italy; 11th Annual Congress of Russian Association of Oncological Urology, 05-07, 2016 Moscow, Russia; 36th International Urology Congress, October 20-23, 2016 Argentina, South America, 27th International Prostate Cancer Update, January 24-27, 2017 Colorado, USA.

Track 14 - Technological Tools in Prostate Cancer

New technology is offering hope that men could one day avoid having to undergo an invasive procedure to determine whether they might have prostate cancer. Pomegranate fruit extracts possess polyphenol and other compounds with ant proliferative and anti-inflammatory effects in prostate. Feeding of pomegranate fruit extract to mice affords substantial protection from the adverse effects of UVB radiation via modulation in early biomarkers of photo carcinogenesis. Biological molecules that provide a clear indication of disease also known as biomarkers are used for molecular tests to diagnose prostate cancer. If patients with multiple lymphomatous polyposis of the gastro intestinal tract have obstructive urinary symptoms, involvement of the prostate gland by lymphoma should be considered, and appropriate diagnostic studies should be performed. The majority of prostate cancer deaths result from metastatic disease, which tends to initially respond to well to chemotherapeutic agents that cause DNA damage. New biomarkers are allowing more precisely detecting prostate cancer, guiding decisions about the therapies we use to treat, monitoring response to treatment and track the progression of cancer.

Related Oncology Conferences | Cancer Conferences | Oncology Meetings

12th World Cancer Conference, September 26-28, 2016 London, UK; 13th Global Oncologists Summit, October 17-19 2016, Dubai, UAE; Global Summit on Melanoma, September 25-26, 2017 Rome, Italy; Multiple Myeloma Conference, October 15-17, 2017 Milan, Italy; Radiology Conference, October 23-25, 2017 Chicago, USA; 6th Annual Asia-Pacific Prostate Society Conference, September 9 -10 Seoul, Korea; 68th Annual German Society of Urology Congress, September 28-October 1, 2016 Leipzig, Germany; 72nd Annual Canadian Urological Association Meeting, June 25-27, 2017 Toronto, Canada; 4th Annual Immuno-Oncology Summit, August 29-September 2, 2016 Boston, USA; 2nd Biomarkers, Diagnostics & Clinical Research Conference, September 19-20 Boston, USA; Biomarkers and Targeted Therapeutics in Sjögren’s (BATTS) Conference, September 19-22, 2016 Oklahoma, USA; NCRI Cancer Conference, November 6-9, 2016 Liverpool, UK; 6th Munich Biomarker Conference, November 29-30, 2016 Munchen, Germany; Annual Meeting of American Association of Genitourinary Surgeons, April 27-30, 2017 Florida, USA.

Track 15 - Prostate Cancer in Market

Growth in the overall urological device market will be driven by improved diagnosis rates, particularly for prostate cancer and benign prostatic hyperplasia. Comparative oncology is the study of prostate cancer that naturally occurs in animals and the comparison to its human counterpart in order to identify treatments and cures that can benefit both humans and animals. Radio Oncology or radiotherapy is therapy using ionizing radiation, generally as part of prostate cancer treatment to control or kill malignant cells. External beam radiation therapy is currently the most frequently used primary treatment method for prostate cancer, but it is predicted to be overtaken by robotic prostatectomy surgery by 2013. Other treatments include brachytherapy, cryotherapy and high-intensity focused ultrasound (HIFU), with the developing market for HIFU estimated to grow at a compound annual growth rate (CAGR) of 91% by 2016.Clinical Oncology encompasses the nonsurgical aspects of cancer care, including therapeutic administration of ionizing radiation and cytotoxic chemotherapy.

Related Oncology Conferences | Cancer Conferences | Oncology Meetings

Molecular Biomarkers Conference, September 15-17 2016 Berlin, Germany; Cervical Cancer Conference, September 22-23 2016, Vienna, Austria; Surgical Oncology Conference, October 23-25, 2017 Chicago, USA; 2nd Cervical Cancer Conference, October 29 -31, 2017 Brussels, Belgium; Cancer World Conventaion, November 26-28, 2017 Frankfurt, Germany; 89th Annual Italian Society of Urology Congress, October 15-18, 2016 Venezia Italy; 62nd Annual Meeting of Czech Urological Society, October 19-21, 2016 Czech Budejovice, Czech Republic; ESMO 2017 Congress, September 08-12, 2017 Madrid, Spain; International Cancer Education Conference, September 14-16, 2016 Bethesda, USA; 16th Biennial Meeting of the International Gynecologic Cancer Society, October 29-31​ Lisbon, Portugal; World Cancer Congress , October 31 - November 3 Paris, France, Malaysia Urology Conference, November 24-28,2016 Kuala Lumpur, Malaysia; Annual AUA Meeting, May 12-16, 2017 Boston, USA.

Track 16- PCa Oncology and Clinical Trials

Clinical scientists and laboratory investigators study the basic biology of prostate cancer to hunt for even better ways to detect it and treat it. Preclinical trials for metastatic prostate cancer and Clinical trials for advanced prostate cancer play a crucial role in moving new treatments to patients. New treatments on prostate cancer include Surgery, Radiation, Hormonal Therapy, Chemo therapy, Biologic therapy and Bisphosphonate therapy. Unlike vaccines against infections like measles or mumps, prostate cancer vaccines are designed to help treat, not prevent, prostate cancer. One possible advantage of these types of treatments is that they seem to have very limited side effects. Drug therapeutics is expected to reach $8.1 billion in 2012 and nearly $18.6 billion in 2017, a CAGR of 18%.

Related Oncology Conferences | Cancer Conferences | Oncology Meetings

Oral Cancer Conference, August 18-20 2016, Portland, USA; Surgical Oncology Conference, August 29-31 2016, Sao Paulo, Brazil; Cancer Diagnostics Conference, May 8-10, 2017 Dubai, UAE; 3rd Prostate Cancer Conference, June 26-28, 2017 Baltimore, USA; Lymphoma Conference, July 24-26, 2017 Rome, Italy; 14th Urological Association of Asia Congress, July 20-24, 2016 Suntec, Singapore; 17th Asia-Pacific Prostate Cancer Conference, August 31- September 3, 2016 Melbourne, Australia; ASCO Genitourinary Cancers Symposium, February, 16-18, 2017 Orlando, USA; 2nd International Prostate Cancer Symposium, August 6 -7, 2016 Moscow, Russia, 13th Meeting of the EAU Robotic Urology Section, September 14-16, 2016 Milan – Italy; 11th Annual Congress of Russian Association of Oncological Urology, 05-07, 2016 Moscow, Russia; 36th International Urology Congress, October 20-23, 2016 Argentina, South America, 27th International Prostate Cancer Update, January 24-27, 2017 Colorado, USA.

Track 17 - State-of-the art: vision on the future

Current state of the art, multimodality research and future visions for the treatment of patients with prostate cancer: consensus results from challenges and chances in prostate cancer research .A urologist, a radiation oncologist, and a medical oncologist will give you the most comprehensive assessment of the available treatments and expected outcomes. Nuclear scans make pictures based on the body’s chemistry rather than on physical shapes and forms PET/CT scanners give information on any areas of increased cell activity. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. Taken together, the prostate biopsy scenario is currently becoming distinctively complex. It has clearly moved far beyond any prostate cancer detection, or avoiding biopsy-related complications such as infections or patients’ anxiety. Importantly, the future of prostate imaging especially of multiparametric MRI-based technology has already begun.

Related Oncology Conferences | Cancer Conferences | Oncology Meetings

12th World Cancer Conference, September 26-28, 2016 London, UK; 13th Global Oncologists Summit, October 17-19 2016, Dubai, UAE; Global Summit on Melanoma, September 25-26, 2017 Rome, Italy; Multiple Myeloma Conference, October 15-17, 2017 Milan, Italy; Radiology Conference, October 23-25, 2017 Chicago, USA; 6th Annual Asia-Pacific Prostate Society Conference, September 9 -10 Seoul, Korea; 68th Annual German Society of Urology Congress, September 28-October 1, 2016 Leipzig, Germany; 72nd Annual Canadian Urological Association Meeting, June 25-27, 2017 Toronto, Canada; 4th Annual Immuno-Oncology Summit, August 29-September 2, 2016 Boston, USA; 2nd Biomarkers, Diagnostics & Clinical Research Conference, September 19-20 Boston, USA; Biomarkers and Targeted Therapeutics in Sjögren’s (BATTS) Conference, September 19-22, 2016 Oklahoma, USA; NCRI Cancer Conference, November 6-9, 2016 Liverpool, UK; 6th Munich Biomarker Conference, November 29-30, 2016 Munchen, Germany; Annual Meeting of American Association of Genitourinary Surgeons, April 27-30, 2017 Florida, USA.

Track 18- Oncologists: Prostate Cancer

An oncologist is a doctor who specializes in treating people with cancer. The oncologist’s research into the causes, prevention, detection, and treatment of prostate is going on in many medical centers throughout the world. The Prostate Cancer World Congress 2016 is the world’s largest multidisciplinary prostate cancer meeting. Understanding the mechanisms of prostate cancer initiation and progression should have a significant impact on development of novel therapeutic approaches that can help to combat the disease. New research on gene changes linked to prostate cancer is helping scientists better understand how prostate cancer develops. Ductal adenocarcinoma often involves the central ducts of the gland and may present as an exophytic papillary lesion in the prostatic urethra. The tumour presents in elderly men with haematuria or obstructive symptoms. For this reason, they are often seen in Transurethral Resection (TUR) specimens and at Radical Prostatectomy (RP), and are less often found in needle biopsies. Researchers continue to look for foods (or substances in them) that can help lower prostate cancer risk. The diabetes drugs will reduce glucose uptake, disrupt glycolysis, and reduce tumor growth without significant side effects in both adenocarcinoma pancreas and prostate. Doctors agree that the prostate-specific antigen (PSA) blood test is not a perfect test for finding prostate cancer early. It misses some cancers, and in other cases it is elevated when cancer isn’t present. Researchers are working on two strategies to address this problem. Newer treatments are being developed, and improvements are being made among many standard prostate cancer treatment methods. Several other types of vaccines to treat prostate cancer are being tested in clinical trials. One example is PROSTVAC, which uses a virus that has been genetically modified to contain prostate-specific antigen (PSA).

Related Oncology Conferences | Cancer Conferences | Oncology Meetings

Molecular Biomarkers Conference, September 15-17 2016 Berlin, Germany; Cervical Cancer Conference, September 22-23 2016, Vienna, Austria; Surgical Oncology Conference, October 23-25, 2017 Chicago, USA; 2nd Cervical Cancer Conference, October 29 -31, 2017 Brussels, Belgium; Cancer World Conventaion, November 26-28, 2017 Frankfurt, Germany; 89th Annual Italian Society of Urology Congress, October 15-18, 2016 Venezia Italy; 62nd Annual Meeting of Czech Urological Society, October 19-21, 2016 Czech Budejovice, Czech Republic; ESMO 2017 Congress, September 08-12, 2017 Madrid, Spain; International Cancer Education Conference, September 14-16, 2016 Bethesda, USA; 16th Biennial Meeting of the International Gynecologic Cancer Society, October 29-31​ Lisbon, Portugal; World Cancer Congress , October 31 - November 3 Paris, France, Malaysia Urology Conference, November 24-28,2016 Kuala Lumpur, Malaysia; Annual AUA Meeting, May 12-16, 2017 Boston, USA.

Track 19 – Prostate Cancer Case Reports 

Prostate cancer case reports play a crucial role in moving new treatments to patients who need those most, securing data so regulatory approvals can be obtained and new drugs can move into widespread clinical practice. Oncology Esthetics is the practice of safe and beneficial spa services by individuals trained to understand how prostate cancer and associated medical treatments affect the body. Prostate Oncology Nutrition includes the current therapies used to treat pediatrics health and nutrition related side effects. Patients who participate in clinical trials provide an invaluable service both to treatment science and fellow patients. If a patient with prostate carcinoma develops metastatic disease of musculoskeletal oncolgy, the bone lesion may become dense and hard. There are currently more than several Phase III drug trials and more than 90 Phase I/II trials in process for prostate cancer in North America and Europe.

Related Oncology Conferences | Cancer Conferences | Oncology Meetings

Oral Cancer Conference, August 18-20 2016, Portland, USA; Surgical Oncology Conference, August 29-31 2016, Sao Paulo, Brazil; Cancer Diagnostics Conference, May 8-10, 2017 Dubai, UAE; 3rd Prostate Cancer Conference, June 26-28, 2017 Baltimore, USA; Lymphoma Conference, July 24-26, 2017 Rome, Italy; 14th Urological Association of Asia Congress, July 20-24, 2016 Suntec, Singapore; 17th Asia-Pacific Prostate Cancer Conference, August 31- September 3, 2016 Melbourne, Australia; ASCO Genitourinary Cancers Symposium, February, 16-18, 2017 Orlando, USA; 2nd International Prostate Cancer Symposium, August 6 -7, 2016 Moscow, Russia, 13th Meeting of the EAU Robotic Urology Section, September 14-16, 2016 Milan – Italy; 11th Annual Congress of Russian Association of Oncological Urology, 05-07, 2016 Moscow, Russia; 36th International Urology Congress, October 20-23, 2016 Argentina, South America, 27th International Prostate Cancer Update, January 24-27, 2017 Colorado, USA.

Track 20 – Entrepreneur Investments Meet

A key ingredient in successful entrepreneurship is self-knowledge. Prostate Cancer-2016 aims to bring together all existing and budding bio entrepreneurs to share experiences and present new innovations and challenges in cancer community. Each year, over a million companies are started in the world with about 5–10 of them classified as high technology companies. Turning ideas into business ventures is tricky and the opportunity-recognition step is critical in new venture creation. This gestalt in the entrepreneur's perception of the relationship between the invention and final product is refined into a business model that describes how the venture will make money or provide an appropriate return to the potential investors. Cancer science is complex and rapidly changing and requires a specialized knowledge to understand the value of the innovation and its competitive position in the industry. This three day community-wide conference will be a highly interactive forum that will bring experts in areas ranging from prostate cancer to signaling pathways to novel therapeutic approaches to the scientific hub. In addition to our outstanding speakers, we will also showcase short talks and poster presentations from submitted abstracts .The speakers will discuss state-of-the-art treatments, current guidelines, clinical challenges, and review recent trial data and emerging therapeutic approaches with the potential to impact clinical practice. This session will include combined efforts of World-renowned speakers, the most recent techniques, developments, and the newest updates in prostate cancer.

Related Oncology Conferences | Cancer Conferences | Oncology Meetings

12th World Cancer Conference, September 26-28, 2016 London, UK; 13th Global Oncologists Summit, October 17-19 2016, Dubai, UAE; Global Summit on Melanoma, September 25-26, 2017 Rome, Italy; Multiple Myeloma Conference, October 15-17, 2017 Milan, Italy; Radiology Conference, October 23-25, 2017 Chicago, USA; 6th Annual Asia-Pacific Prostate Society Conference, September 9 -10 Seoul, Korea; 68th Annual German Society of Urology Congress, September 28-October 1, 2016 Leipzig, Germany; 72nd Annual Canadian Urological Association Meeting, June 25-27, 2017 Toronto, Canada; 4th Annual Immuno-Oncology Summit, August 29-September 2, 2016 Boston, USA; 2nd Biomarkers, Diagnostics & Clinical Research Conference, September 19-20 Boston, USA; Biomarkers and Targeted Therapeutics in Sjögren’s (BATTS) Conference, September 19-22, 2016 Oklahoma, USA; NCRI Cancer Conference, November 6-9, 2016 Liverpool, UK; 6th Munich Biomarker Conference, November 29-30, 2016 Munchen, Germany; Annual Meeting of American Association of Genitourinary Surgeons, April 27-30, 2017 Florida, USA.

Conference Series LLC  invites all the participants from all over the world to attend ‘2nd International Conference on Prostate Cancer and Therapeutics’ to be held during August 22-23, 2016 at Philadelphia, USA which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions. 

Prostate Cancer2016 is the learning of latest treatment options, lifestyle changes, and quality of life issues presented by world-renowned physicians and researchers on Prostate Cancer. The studies are more concerned with the interactions of top experts from key specialties involved in the care of patients with prostate cancer to discuss state-of-the-art treatments and current guidelines, debate controversies and clinical challenges, and review recent trial data and emerging therapeutic approaches with the potential to impact clinical practice. Advanced studies are being made to improvise developments in drugs to treat numerous diverse prostate cancer disorders, including prostatitis, benign prostatic hyperplasia, bone pain, erectile dysfunction and many more. Conference Series LLC organizes a conference series of 1000+ Global Events inclusive of 300+ Conferences, 500+ Upcoming and Previous Symposiums and Workshops in USA, Europe & Asia with support from 1000 more scientific societies and publishes 700+ Open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members.

Why to attend???
With members from around the world focused on learning about prostate cancer and its advances; this is your best opportunity to reach the largest assemblage of participants from the prostate cancer research community. Conduct presentations, distribute information, meet with current and potential scientists, make a splash with new drug developments, and receive name recognition at this 3-day event. World-renowned speakers, the most recent techniques, developments, and the newest updates in prostate cancer are hallmarks of this conference. 

Target Audience:

  • Medical oncologists
  • Radiation oncologists
  • Surgeons
  • Urologists
  • Fellows
  • Nurse practitioners and Nurses
  • Physician assistants
  • Pharmacists
  • Health care professionals
  • Business Entrepreneurs
  • Prostate Cancer Associations and Societies

Overall Market of Prostate Cancer with Statistics

Prostate cancer is the most frequently diagnosed cancer in men. In terms of loss of life from any disease, prostate cancer ranks eleventh; and it ranks sixth in terms of cancer-related mortality in men. The prostate cancer market has a huge demand for new and novel drugs that address unmet needs such as improved survival time, less toxicity, increased progression free survival, increased effectiveness, and lower cost. The market from 2005 to 2020 covering 21 major drugs categorized into four therapies; namely hormonal therapy, chemotherapy, immunotherapy, and targeted therapy. Out of 21 drugs, 13 are currently commercially available in the market and 8 are in pipeline. The need for consensus amongst academia and business has been recognized by Conference Series LLC and so we are proud to host the International Conference on Prostate Cancer.

Region wise Scope

Prostate cancer is the second leading cause of cancer death in American men, behind only lung cancer. About 1 man in 38 will die of prostate cancer. Prostate cancer can be a serious disease, but most men diagnosed with prostate cancer do not die from it. In fact, more than 2.9 million men in the United States who have been diagnosed with prostate cancer at some point are still alive today. Prostate cancer occurs mainly in older men. About 6 cases in 10 are diagnosed in men aged 65 or older, and it is rare before age 40. The average age at the time of diagnosis is about 66.

Why Philadelphia?

Philadelphia is the largest city in the Commonwealth of Pennsylvania, the second largest city on the East Coast of the United States, and the fifth-most-populous city in the United States. It is located in the Northeastern United States along the Delaware and Schuylkill rivers, and it is the only consolidated city-county in Pennsylvania. Philadelphia is the economic and cultural centre of the Delaware Valley, home to over 6 million people and the country's sixth-largest metropolitan area. Within the Delaware Valley, the Philadelphia metropolitan division consists of five counties in Pennsylvania and has a population of 4,008,994. Popular nicknames for Philadelphia are Philly and The City of Brotherly Love.

The city is the centre of economic activity in Pennsylvania, and is home to the Philadelphia Stock Exchange and several Fortune 500 companies.
Philadelphia is known for its arts and culture. The cheese steak and soft pretzel are emblematic of Philadelphia cuisine, which is shaped by the city's ethnic mix. The city has more outdoor sculptures and murals than any other American city, and Philadelphia's Fairmount Park is the largest landscaped urban park in the world.

Nowadays the vibrant city is modernized yet still pieces of history are evident. If you would like to visit either for business or holidays, there is a huge variety of holiday accommodation to choose from and compare with from leading five star hotels to budget motels. Spoil yourself in the exciting range of restaurants and visit attractions to get a real classic feel of the place. Pennsylvania is a great place to start a business, it's one of the most business friendly states in the US. It offers easy access to capital, low tax rate, and numerous colleges and universities so access to top quality brain power is easy.

Conference Highlights

Latest Research on Prostate Cancer

Treating Prostate Cancer

Living with Prostate Cancer

Diagnosis, Staging and Treatment of Prostate Cancer

Managing Possible Side Effects of Prostate Cancer Treatments

Recurrent Prostate Cancer Treatment

Prostate Cancer: Symptoms and Signs

New Treatment for Enlarged Prostate

Men need to know about Prostate Cancer

 

Why attend???

As mentioned earlier, prostate cancer research, involves people from various disciplines and people form such various fields do not always get a chance to meet and discuss the current developments in their respective areas. Prostate Cancer conferences seek to bring all such people together and thereby provide them a platform with which to discuss and exchange ideas with one another. The prostate cancer conference is set to be graced by World-renowned speakers who will shed light on the most recent techniques, tactics, and the newest updates in Prostate Cancer Research.

Lists of Societies related to Prostate cancer:

American Cancer Society

Prostate Cancer Foundation

Cancer Research UK

British Association of Urological Surgeons (BAUS)

National Cancer Institute

Prostate Cancer UK

Prostate Cancer Canada

Australian Prostate cancer Research Centre

Prostate Cancer Foundation of Australia

Urological Association of Asia and Iranian

 

Target Audience:

The target audience would include medical oncologists, radiation oncologists, surgeons, and urologists involved in the treatment and management of patients with prostate cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals interested in the treatment of prostate cancer may also participate.

 Members Associated with Prostate Cancer Research:

 

Hospitals Associated with Prostate Cancer Research:

 

 

Societies Associated with Prostate Cancer Research

 

 

Industries Associated with Prostate Cancer Research

 

 

Universities Associated with Prostate Cancer Research

 

 

Market Value Prostate Cancer Research

 

 

Glance at Market of Prostate Cancer Related Products:

 

Growing prostate cancer population (25% increase in the incidence of prostate cancer in mature countries and 40% increase in emerging countries, from 2010 to 2020) is an impetus for the growth of the market. This factor, along with increasing number of innovative drugs estimated to get launched in short-term future and increasing old age male population are driving the growth of the market at an expected CAGR of 9% from 2010 to 2020. In 2010, among the mature markets, U.S. was the major contributor; accounting for 35% of the total sales of prostate cancer drugs and amongst the emerging countries, China contributed to the share of about 2% of the overall prostate cancer therapeutics market.

 

Market Growth of Prostate Cancer Research in the last and upcoming ten years

 

 

Products Manufactured by the industry related Prostate Cancer Research

Jevtana (cabazitaxel)
sanofi aventis; For the treatment of prostate cancer, Approved June 2010

Provenge (sipuleucel-T)
Dendreon; For the treatment of hormone refractory prostate cancer, Approved May 2010

Zytiga (abiraterone acetate)
Centocor Ortho Biotech; For the treatment of prostate cancer, Approved May 2011

Xtandi (enzalutamide)
Medivation; For the treatment of metastatic castration-resistant prostate cancer, Approved August 2012

Xofigo (radium Ra 223 dichloride)
Bayer Healthcare Pharmaceuticals; For the treatment of prostate cancer with bone metastases, Approved May 2013

 

Fund Allotment to Prostate Cancer Research

 

References:

http://www.cancer.gov/research/progress/snapshots/prostate

http://www.marketsandmarkets.com/Market-Reports/prostate-cance-drugs-market-413.html

http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-key-statistics

http://cancer.uchicago.edu/community/chicago.shtml

http://prostatecancerinfolink.net/tips-tools/us-based-prostate-cancer-web-sites/

http://www.prostatecancerroundtable.net/member-list/http://www.cancer.org/cancer/news/expertvoices/post/2013/06/13/choosing-the-best-prostate-cancer-treatment-for-you.aspxhttp://www.cancer.org/cancer/prostatecancer/

http://www.dattolifoundation.org/information.htm

http://www.uaa.alaska.edu/wwami/apply/usamedicalschools.cfm

http://www.prnewswire.com/news-releases/prostate-cancer-treatment-will-drive-the-us-market-for-urological-devices-to-double-in-value-by-2016-80691152.html

http://www.bccresearch.com/pressroom/phm/global-prostate-cancer-market-reach-$50.3-billion-2017

http://www.conference-service.com/conferences/oncology.html

https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology

https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology

http://www.cancer.gov/research/progress/snapshots/prostate

http://www.bccresearch.com/pressroom/phm/global-prostate-cancer-market-reach-$50.3-billion-2017

http://www.prnewswire.com/news-releases/prostate-cancer-treatment-will-drive-the-us-market-for-urological-devices-to-double-in-value-by-2016-80691152.html

http://cancer.uchicago.edu/community/chicago.shtml

http://www.chicagomag.com/Chicago-Magazine/January-2012/Top-Doctors-in-Chicago-Cancer-Specialists/

http://www.auanet.org/international/faculty-directory.cfm?continent=North-America

http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-key-statistics

http://www.marketsandmarkets.com/Market-Reports/prostate-cance-drugs-market-413.html

Prostate Cancer-2015

We would like to thank all of our wonderful speakers, conference attendees, students, associations and guests for making Prostate Cancer-2015 a wonderful event!

Conference Series LLC hosted International Conference on Prostate Cancer scheduled during June 22-24, 2015 at Hyatt Regency Orlando International Airport Hotel, Florida, USA with the theme “Advancement in Prostate Cancer Research and Treatment”

The conference had multiple sessions, Keynote presentations, panel discussions and Poster sessions. We received active participation from various scientists, researchers, students and leaders from the field of Pharmacology who made this event successful.

Various sessions were carried out with multiple presentations from speakers all around the world. Major Sessions to be discussed were:

  • Current and Future Perspectives on Prostate Cancer
  • Benign Prostatic Hyperplasia
  • Treatments for Castration Resistant Prostate Cancer
  • Translational Research and Pathology
  • Screening and early diagnosis of prostate cancer
  • Prostatitis
  • Radical Prostatectomy
  • PCa Oncology and Clinical Trials on Prostate Cancer

The conference was initiated with a series of lectures delivered by both Honorable Guests and members of the Keynote forum. The list includes:

  • Qun Lu, East Carolina University, USA
  • Veronica J James, Australian National University, Australia
  • Taisei Nomura, Osaka University, Japan
  • Fahri Saatcioglu, University of Oslo, Norway
  • Steve Assinder, Andrology Research Group, Australia

Workshop includes professional presentation by Lucia Languino, Professor, Thomas Jefferson University, USA on “Molecular Mechanisms of Prostate Cancer Progression

Conference Series LLC thank all our expert presenters from all around the world which includes various outside experts, University representatives and other eminent researchers who supported the conference by facilitating the discussion forums.

With the grand success of Prostate Cancer-2015, Conference Series LLC take the immense pleasure to announce the “2nd International Conference on Prostate Cancer and Treatment" to be held during August 22-23, 2016 at Philadelphia, Pennsylvania, USA

For more details please visit: http://prostatecancer.cancersummit.org/

 


Past Reports  Proceedings  Gallery  

Cancer Science-2014

OMICS International hosted 4th World Congress on Cancer Therapy during October 20-22, 2014 at Park Regis Chicago, USA with the theme “Enhanced diagnosis, treatment and management of different cancers". The conference had multiple sessions, Keynote presentations, panel discussions and Poster sessions. We received active participation from various scientists, researchers, students and leaders from the field of oncology who made this event successful. The conference was initiated with a series of lectures delivered by both Honorable Guests and members of the Keynote forum. The list includes:

Jeffrey B Ulmer ( University of Regina), Dr. Sudhakar Akul Yakkanti(Stanford Research Institute (SRI) International, Menlo Park, California), Reza Hakkak(Professor of Pediatrics in the College of Medicine), OMICS International thank all our expert presenters from all around the world which includes various outside experts, University representatives and other eminent researchers who supported the conference by facilitating the discussion forums.


Past Reports  Gallery  

Cancer Science-2013

The 3rd World Congress on Cancer Science & Therapy was organized by OMICS Group Inc., during October 21-23, 2013 at Double Tree by Hilton Hotel San Francisco Airport, USA. The conference was marked with the attendance of young and brilliant researchers, business delegates and talented student communities representing more than 25 countries, who have driven this event into the path of success. The conference had multiple sessions, Keynote presentations, panel discussions and Poster sessions. Dr. Jimmy T. Efird, Brody School of Medicine, USA Was honorable Moderator for the conference. The conference proceedings were carried out through various Keynote-presentations by: Dr. Stewart Sell, Wadsworth Center, USA, Dr. Michael Retsky, Harvard School of Public Health, USA, Dr. Jimmy T. Efird, Brody School of Medicine, USA and the wonderful workshop session was organized by Dr. Dorothee Herlyn, The Wistar Institute, USA.

 


Past Reports  Gallery  

Cancer Science-2012

OMICS International 2nd World Congress on Cancer Science & Therapy was held during September 10-12, 2012 at Hilton San Antonio Airport, San Antonio, USA.

The conference proceedings were carried out through effectual keynote lectures by:Dr. Sudhakar Akul Yakkanti, Boys Town National Research Hospital, USA,Dr. Alexei G. Basnakian, University of Arkansas for Medical Sciences, USA,Dr. Dan Dixon, University of South Carolina, USA,Dr. Sophia Ran, Southern Illinois University School of Medicine, USA, Dr. Homer S Black, Baylor College of Medicine, USA

We sincerely thank the Organizing Committee Members for their gracious presence, support, and assistance towards the success of Cancer Science-2012. 


Past Reports  Gallery  

sponsor

Want to Differentiate your company from your competitors and broaden your competitive edge?

Use our global platform of 3000+ Global Events

  • 25 Million+ Visitors to our Global website (conferenceseries.com)
  • 20000+ Unique Visitors per conference
  • 60000+ Page views per conference

For customized sponsorship opportunities at our conferences, or to place an ad on our websites, contact at sponsors@conferenceseries.com or call at: +1-650-268-9744

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date August 22-23, 2016
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity Day 1 Day 2
Poster Opportunity Available

Conferenceseries Destinations


Mail us at

Drop us an email for Program enquiry.
prostatecancer@insightconferences.com
Sponsors / Exhibiting / Advertising.
prostatecancer@conferenceseries.net
General Queries.
prostatecancer@oncologymeet.com

View Proceedings of Previous Conferences

Prostate Cancer-2015
Cancer Therapy - 2015
Euro Cancer Summit - 2015
Cancer Summit - 2015
Authorization Policy

By registering for the conference you grant permission to Conferenceseries LLC to photograph, film or record and use your name, likeness, image, voice and comments and to publish, reproduce, exhibit, distribute, broadcast, edit and/or digitize the resulting images and materials in publications, advertising materials, or in any other form worldwide without compensation. Taking of photographs and/or videotaping during any session is prohibited. Contact us for any queries.